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INTRODUCTION
Among the pharmacological drugs used in psychiatry, lithium is the oldest drug still being 
used regularly. After its initial use by the Danish 
neurologist Lange in the nineteenth century and its 
subsequent (re)discovery by the Australian psychiatrist 
Cade in 1949, the efficacy of lithium in the long-term 
treatment of bipolar disorder was finally established 
by Schou and his Danish colleagues in the 1960ies 
which led to its registration in Europe and the US as 
well as many other countries in the 1970ies (1). 
Nowadays, lithium is considered in many guidelines 
as one of the major options, if not the first choice in 
the long-term maintenance treatment of bipolar 
disorder. Nevertheless, it is not being used as 
frequently as what one would expect based on its 
place in these guidelines. In most countries, several 
other drugs which have become available as 
alternatives, i.e. the anticonvulsants carbamazepine, 
valproate and lamotrigine and several atypical 
antipsychotics which all are also registered for the 
long-term treatment of bipolar disorder, are being 
used more frequently. This despite the fact that in 
most guidelines they are not recommended as (single) 
first option, but only as one of the (first) options or 
even as second or third option.
 What are the reasons for this apparent
 discrepancy? 
 It cannot be the lack of good efficacy data, as 
especially in recent years a new study and two meta-
analyses have unequivocally shown that lithium is 
efficacious. In 2011, the so far largest study on the 
efficacy of lithium in the maintenance treatment of 
bipolar disorder was published (2). In this double-
blind trial, bipolar I patients who had responded to 
and had tolerated quetiapine were randomized to 
continue with quetiapine or to switch to lithium or 
placebo. The results showed that both quetiapine and 
lithium were more effective than placebo in the 
prevention of any mood episodes, manic episodes and 
depressive episodes. Quetiapine was also more 
effective than lithium in the prevention of any mood 
episodes and depressive episodes, but this result 
should be interpreted with caution as the study design 
was enriched for quetiapine (see above) but not for 
lithium. The two recent meta-analyses, in which the 
Weisler study was included, confirmed the efficacy of 
lithium when concluding that “with no other drug 
available having such ample and consistent evidence 
for its efficacy, lithium remains the most valuable 
treatment option in this indication” (3) and that 
‘lithium seems to be the most reasonable candidate for 
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a first-line option for the long-term treatment of 
bipolar disorder’ (4).
 Another benefit of lithium is its anti-suicidal effect, 
which appears to be at least partially independent of its 
mood stabilizing effect as lithium may also decrease 
aggression and impulsivity. In a recent review with 
data from RCTs as well as naturalistic cohort studies 
Lewitzka et al. (5) concluded that “compelling evidence 
provides strong support that lithium has a suicide 
protective effect over the long-term course in patients 
with mood disorders.” Its anti-suicidal effect in bipolar 
disorder was further supported in a recent Finnish 
nationwide registry-based study among bipolar 
patients hospitalized because of a suicide attempt 
between 1996 and 2003 (n=826) (6). The authors 
looked whether medication use was associated with 
hospitalization due to attempted suicides, deaths from 
suicide, and overall mortality during follow-up. 
Compared to no use, the use of lithium was associated 
with a (non-significantly) lower risk of suicide attempts, 
and with significantly decreased suicide mortality 
(RR=0.39, 95% CI=0.17-0.93, p=0.03) while the use of 
valproic acid (RR=1.53, 95% CI=1.26-1.85, p<0.001), 
antidepressants (RR=1.49, 95% CI=1.23-1.8, p<0.001) 
and benzodiazepines (RR=1.49, 95% CI=1.23-1.80, 
p<0.001) were all associated with an increased risk of 
attempted suicide and the use of antipsychotics did not 
reach statistical significance. This illustrates that 
lithium, despite its small therapeutic window and 
associated risks of an overdose, can be safely prescribed, 
if not should be seriously considered in suicidal bipolar 
patients.
 If the well-established benefits of lithium are not the 
reason for its relative low use, it may be its potential 
harms. Lithium can lead to many adverse effects, of 
which especially its renal effect is considered a major 
harm. One of the major limitations of the above (and 
all other) meta-analyses is that while they looked at not 
only efficacy but also tolerability and overall 
satisfaction, their scope was never more than two 
years. However, when choosing a drug for long-term, 
if not life-long treatment, one should look at efficacy 
and safety not only during the first years of its use but 
also thereafter. While the use of lithium over more than 
10 years is associated with the risk of chronic kidney 
dysfunction (CKD), the long-term use of atypical 
antipsychotics (as its major alternatives) is associated 
with metabolic syndrome and an increased mortality 
risk due to cardiovascular problems. Although it has 
not yet been established how these late adverse effects 
have an impact on the long-term safety of lithium and 
the atypical antipsychotics, the assumption is that also 
over a period of 10 or more years the safety of lithium 
is at least in balance with that of most atypical 
antipsychotics. However, it would be interesting to see 
studies in patients with bipolar disorder looking at 
mortality during treatment with lithium and its 
alternatives over more than 10 years, as has already 
been done with clozapine versus other antipsychotics 
in patients with schizophrenia (7).
 What The Recent Studies have Indicated?
 Three recent studies shed new light on lithium’s 
potential harms. The first study (8) was a nationwide 
population-based study in Denmark, one of the 
countries with traditionally a relative high use of 
lithium, although lithium is no longer the most 
frequently prescribed drug in patients with bipolar 
disorder in Denmark (9). The study aimed to compare 
rates of CKD and in particular rates of end-stage CKD 
among individuals exposed to successive prescriptions 
of lithium, anticonvulsants, or other drugs used for 
bipolar disorder. Two cohorts were compared: cohort 
1 comprised a randomly selected sample of 1.5 million 
individuals among all persons who were registered in 
Denmark in 1995, all patients with a diagnosis of a 
single manic episode or bipolar disorder between 1994 
and 2012 (n =10.591), and all patients exposed to either 
lithium (n =26.731) or anticonvulsants (n=420.959). 
Cohort 2 included only the subgroup of 10.591 patients 
diagnosed as having bipolar disorder. 
 In cohort 1, 0.8%, 1.0%, and 0.2% and in cohort 2 
and 2.6%, 3.0%, and 0.6% were diagnosed as having 
possible, definite, or end-stage CKD, respectively. 
Based on the total sample and not considering 
diagnoses (cohort 1), use of lithium was associated 
with an increased rate of definite CKD (0 prescriptions: 
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hazard ratio [HR]=1.09, 95% CI=0.81-1.45; ≥60 
prescriptions: HR=3.65, 95% CI=2.64-5.05; p for 
trend < 0.001) and possible CKD (0 prescriptions: 
HR=1.01, 95% CI=0.79-1.30; ≥60 prescriptions: 
HR=2.88, 95% CI=2.17-3.81; p for trend <0 .001), 
whereas use of anticonvulsants, antipsychotics, or 
antidepressants were not. Remarkably, neither use of 
lithium nor use of any other drug class was associated 
with increasing rates of end-stage CKD. 
 In patients with bipolar disorder (cohort 2), use of 
lithium was also associated with an increased rate of 
definite CKD (1-2 prescriptions: HR=0.89, 95% 
CI=0.39-2.06; ≥60 prescriptions: HR=2.54, 95% 
CI=1.81-3.57; p for trend <0.001) or possible CKD (1-2 
prescriptions: HR=1.26, 95% CI=0.65-2.43; ≥60 
prescriptions, HR=2.48, 95% CI=1.80-3.42; p for 
trend <0.001). Surprisingly, the use of anticonvulsants 
was also associated with definite CKD (1-2 
prescriptions: HR=1.23, 95% CI=0.76-1.99; ≥60 
prescriptions, HR=2.30, 95% CI=1.53-3.44; p for 
trend <0 .001) and with possible CKD (1-2 
prescriptions: HR=1.11, 95% CI=0.70-1.76; ≥60 
prescriptions: HR=1.97, 95% CI=1.34-2.90; p for 
trend <0.001). There was no such association with 
antipsychotics or antidepressants. Also in patients 
with bipolar disorder, use of lithium was not 
significantly associated with an increased rate of end-
stage CKD, whereas use of anticonvulsants was (1-2 
prescriptions, HR=0 [95% CI, 0.00-infinity]; 30-39 
prescriptions: HR=3.23, 95% CI=1.26-8.27; ≥60 
prescriptions: HR=2.06, 95% CI=0.82-5.16; p for 
trend=0.002). This latter finding of increased CKD 
among patients using anticonvulsants may be 
explained by selective prescription of these drugs to 
patients with already existing CKD, including patients 
with prior lithium use who had developed CKD. 
Nevertheless, the authors conclude: “Maintenance 
treatment with lithium or anticonvulsants as practiced 
in modern care [WN: i.e. with regularly monitoring of 
kidney function and lithium plasma levels] is associated 
with an increased rate of CKD. However, use of 
lithium is not associated with an increased rate of end-
stage CKD.”
 In the second study looking at laboratory data from 
the Oxford region (UK) Shine et al. (10) investigated the 
incidence of renal, thyroid, and parathyroid dysfunction 
in patients (aged ≥18 years) having used lithium and 
who had at least two creatinine, thyrotropin, calcium, 
glycated hemoglobin, or lithium measurements 
between 1982 and 2014 (n=2.759), compared with 
controls who did not have lithium measurements taken 
(n=689.229). Lithium use was associated with an 
increased risk of stage three CKD (HR=1.93, 95% 
CI=1.76-2.12; p<0.0001). Furthermore, lithium use was 
associated with hypothyroidism (2.31, 2.05-2.60; 
p<0.0001) and raised total serum calcium concentration 
(1.43, 1.21-1.69; p<0.0001),  but not with 
hyperthyroidism (1.22, 0.96-1.55; p=0.1010) or raised 
adjusted calcium concentration (1.08, 0.88-1.34; 
p=0.4602). The adverse effects occurred early in 
treatment (HR<1 for length of treatment with lithium), 
possibly biased by stopping lithium in patients who 
developed the adverse event. Higher than median 
lithium concentrations were associated with increased 
risk of all adverse outcomes. Also this study shows that 
use of lithium is definitely associated with severe 
adverse effects, but fortunately very severe outcomes 
such as end stage CKD or increased mortality do not 
appear to be increased.
 Lithium Intoxication
 A final serious problem associated with the use of 
lithium is the risk of lithium intoxication, which can be 
the result of a deliberate overdose as suicide attempt, 
but also the result of a chronic intoxication, e.g. to 
insufficient water (and salt) intake or concomitant use 
of other drugs lowering the excretion of lithium and 
thus leading to increased lithium plasma levels (11,12). 
Although lithium intoxications can be serious and can 
lead to serious and lasting damage, such as a cerebellar 
syndrome, it can be prevented by extensive 
psychoeducation, the use of a warning system in 
monitoring the prescription of concomitant drugs, and 
last but not least by frequent monitoring of not only 
lithium plasma levels, but also kidney function 
(creatinine), thyroid function (T4 and TSH), and 
parathyroid parameters. 
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 CONCLUSION
 Given its excellent efficacy and despite its potential 
adverse effects, lithium should be considered as the 
first choice in every patient with bipolar disorder with 
an indication for maintenance treatment (13). 
Furthermore, its use requires experienced doctors, and 
in my opinion treatment of our bipolar patients 
preferentially in centers specialized in the treatment of 
bipolar patients with lithium.
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